The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
This is the first of its kind vaccine for Covid 19 to get the go-ahead
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
A veteran in cell therapy and oncology commercialisation
Advances deployment of mRNA technology across vaccines and therapeutics development
CDSCO to fast-track trials and approval for COVID19 vaccine
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
Subscribe To Our Newsletter & Stay Updated
